Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I-II Study of NBTXR3 Activated by Sterostatic Body Radiation Therapy (SBRT) In the Treatment of Liver Cancers

Next Previous
X
Search
Trial Profile

A Phase I-II Study of NBTXR3 Activated by Sterostatic Body Radiation Therapy (SBRT) In the Treatment of Liver Cancers

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hafnium oxide (Primary) ; Hafnium oxide (Primary)
  • Indications Liver cancer; Liver metastases
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Nanobiotix

    • Most Recent Events

    • 13 Sep 2022 Results of an analysis assessing feasibility and safety from phase I trials: NCT02379845, NCT01946867, NCT02721056, NCT03589339, NCT04484909, NCT04615013 and NCT02805894 presented at the 47th European Society for Medical Oncology Congress
    • 05 May 2021 Status changed from active, no longer recruiting to discontinued.
    • 17 Jan 2021 Results (n=23) from phase 1 part presented at the 2021 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top